Pathos strikes $2.2B Alphamab ADC licence and AstraZeneca pact to build AI-native oncology pipeline

Pathos, the US clinical-stage AI and technology company, announced on 4 August 2026 two back-to-back cancer deals to expand its AI-native oncology pipeline.

Under a global licensing agreement with Alphamab Oncology worth up to roughly $2.2 billion, Pathos gains rights to JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC). In a separate collaboration with AstraZeneca, the companies will advance AZD4241, a preclinical investigational therapy for patients with estrogen receptor-positive breast cancer.

Pathos said the agreements pair external clinical- and preclinical-stage assets with its AI drug-development platform, deepening its oncology pipeline across ADC and targeted-therapy modalities.

Source: Pathos AI press release via Business Wire, 4 August 2026.